



Title	Contrast-enhanced harmonic endoscopic ultrasonography in gallbladder cancer and pancreatic cancer
Author(s)	Sugimoto, Mitsuru; Takagi, Tadayuki; Suzuki, Rei; Konno, Naoki; Asama, Hiroyuki; Watanabe, Ko; Nakamura, Jun; Kikuchi, Hitomi; Waragai, Yuichi; Takasumi, Mika; Sato, Yuki; Hikichi, Takuto; Ohira, Hiromasa
Citation	Fukushima Journal of Medical Science. 63(2): 39-45
Issue Date	2017
URL	http://ir.fmu.ac.jp/dspace/handle/123456789/639
Rights	© 2017 The Fukushima Society of Medical Science
DOI	10.5387/fms.2017-04
Text Version	publisher

[Review]

Contrast-enhanced harmonic endoscopic ultrasonography in gallbladder cancer and pancreatic cancer

Mitsuru Sugimoto¹⁾, Tadayuki Takagi¹⁾, Rei Suzuki¹⁾, Naoki Konno¹⁾, Hiroyuki Asama¹⁾, Ko Watanabe^{1,2)}, Jun Nakamura^{1,2)}, Hitomi Kikuchi^{1,2)}, Yuichi Waragai¹⁾, Mika Takasumi¹⁾, Yuki Sato¹⁾, Takuto Hikichi²⁾ and Hiromasa Ohira¹⁾

¹⁾Department of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima Japan, ²⁾Department of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan

(Received February 22, 2017, accepted February 22, 2017)

Abstract

Endoscopic ultrasonography (EUS) plays a major role in diagnosing gallbladder (GB) cancer and pancreatic cancer (PC). In cases of GB cancer, EUS allows for precise observations of morphology and wall layers. However, proficiency is required for the morphologic diagnosis of GB tumors. Therefore, contrast-enhanced harmonic EUS (CH-EUS) began to be performed to diagnose GB lesions. CH-EUS enables real-time observation of the hemodynamics of GB tumors. The enhanced patterns generated by CH-EUS improve precision in the diagnosis of such tumors.

PC appears as a hypoechoic mass on EUS. However, distinguishing between PC and mass-forming pancreatitis or focal autoimmune pancreatitis (AIP) is difficult via conventional EUS. CH-EUS allows for differentiating among these diseases (PC is hypoenhanced and heterogeneously enhanced, pancreatitis is isoenhanced, and a pancreatic neuroendocrine tumor is hyperenhanced). EUS-guided fine needle aspiration (EUS-FNA) also contributes to pathological diagnoses of pancreatic lesions. However, certain PC patients cannot be diagnosed via EUS-FNA. PC is heterogeneously enhanced on CH-EUS, and unenhanced regions have been reported to be areas of fibrosis or necrosis. CH-EUS-guided fine needle aspiration (CH-EUS-FNA) permits puncturing of the enhanced area while avoiding necrotic and fibrotic regions. Moreover, as CH-EUS findings have been quantitatively analyzed, a time-intensity curve (TIC) has become usable for diagnosing solid pancreatic lesions. CH-EUS-related techniques have been developed and increasingly utilized in the pancreaticobiliary area.

Introduction

Biliary tract cancer and pancreatic cancer (PC) have poor prognoses. More precise methods for diagnosing these diseases were desired. Endoscopic ultrasonography (EUS) has played an important role in diagnosing gallbladder (GB) cancer and PC¹⁻⁵⁾. However, when EUS is used, GB cancer must be diagnosed morphologically, and it is difficult to differentiate between pancreatic inflammatory tumor-like lesions and PC^{6,7)}.

Recently, contrast-enhanced harmonic EUS (CH-EUS) was reported to be useful in diagnosing

pancreaticobiliary diseases⁸⁻²⁷⁾. In this report, we describe the efficacy of CH-EUS in diagnosing GB cancer and PC, including in experiments at our institution.

Contrast agent for ultrasound

Ultrasound contrast agents have been classified based on their ability to cross the pulmonary arterial bed and their motion under an ultrasound beam with a low mechanical index (MI) (Table 1)²⁸⁾.

Historically, Levovist (Schering, Berlin, Germany) was widely used for contrast-enhanced ab-

Table 1. Ultrasound contrast agents

	Passes through the pulmonary arterial bed	Response MI	Diameter of microbubbles (μm)	Gas	Shell	Developer
Echovist [®]	×		99% < 12.0 95% < 8.0	Air	Galactose	Schering
Albunex [®]	○	High	4.3	Air	Albumin	MBI Mallinckrodt
Levovist [®]	○	High	2.0-4.0	Air	Galactose	Schering
Echogen [®]	○	Low	3.0-5.0	Perfluoropentane	Surfactant	Sonus Abbott
Optison [®]	○	Low	3.0-4.5	Perfluoropentane	Albumin	MBI Amersham Health
Definity [®]	○	Low	1.1-3.3	Perfluoropentane	Phospholipids	ImaRx, Bristol-Myers
Imavist TM	○	Low	5.0	Perfluoropentane	Phospholipids	Alliance
SonoVue [®]	○	Low	2.5	Sulfur hexafluoride	Phospholipids	Bracco
Sonazoid TM	○	Low	3.0	Perflubutane	Lipids	GE Healthcare

MI, Mechanical index

dominal ultrasonography. Levovist features air surrounded by a galactose shell. When Levovist is used, enhanced images are created from harmonic signals received when microbubbles are destroyed by high MI ultrasound. Therefore, for continued observation, contrast agents must be repeatedly injected and destroyed.

However, second-generation contrast agents are used today. In particular, SonoVue (Bracco, Milan, Italy) and Sonazoid (GE Healthcare, Little Chalfont, United Kingdom) have been used for pancreaticobiliary CH-EUS. These microbubbles of contrast agents resonate under low MI ultrasound without being destroyed. Thus, second-generation contrast agents have allowed for the prolonged observation of enhancement effects.

Methods of CH-EUS

In our hospital, the endoscopes and ultrasonic equipment used for CH-EUS are GF-UCT260 and GF-UE260 ultrasound gastrovideoscopes (Olympus Medical Systems, Tokyo, Japan), the ProSound α -10 ultrasound system (Aloka, Tokyo, Japan), and the EU-ME2 ultrasound processor (Olympus Medical Systems, Tokyo, Japan). Ideally, patients are adequately sedated with midazolam or another agent prior to endoscope insertion. After target lesions are visualized on the monitor in the B and extended pure harmonic detection (ExPHD) modes, 0.015 mL/kg of the contrast medium (16 μg of Sonazoid in 2 mL of distilled water) is injected. Subsequently, the target lesions are evaluated in the arterial and early venous phases that occur approximately 90

seconds after these lesions are enhanced^{15,29}.

CH-EUS using first-generation enhancing agents for GB cancer

Several investigators have previously described the superiority of EUS relative to abdominal ultrasonography (US) for diagnosing neoplastic GB lesions (adenomas and adenocarcinomas)^{1,2,30,31}. However, these reports did not intend to imply that EUS can only be used to diagnose GB adenocarcinomas. The efficacy of CH-EUS for diagnosing GB malignant lesions has also been reported. In 1997 and 1998, Hirooka *et al.*^{8,10} observed that the visualization of GB adenocarcinoma was enhanced by the contrast medium Albunex, a first-generation enhancing agent (Table 1). In those studies, 11 GB adenocarcinoma patients (91.7%) exhibited enhancement effects, but such effects were not observed for patients with adenocarcinoma or cholesterol polyps.

CH-EUS using second-generation enhancing agents for GB cancer

Recently, the differentiation of GB lesions via CH-EUS with second-generation enhancing agents (SonoVue or Sonazoid) has been reported. In these reports, GB polyps were diagnosed based on enhanced patterns.

Choi *et al.*¹³ and Park *et al.*¹⁴ described the efficacy of CH-EUS with the contrast medium SonoVue. Choi *et al.*¹³ reported that irregular vessels observed via CH-EUS were useful in the diagnosis of malignant polyps, with a sensitivity and a specificity of

90.3% and 96.6%, respectively. Furthermore, perfusion defects observed via CH-EUS could be used to efficiently diagnose malignant polyps, with a sensitivity and a specificity of 90.3% and 94.9%, respectively. In addition, when using SonoVue and the same procedures, Park *et al.*¹⁴ found that 80% (8/10) of GB adenocarcinomas were heterogeneously enhanced and that 75% of GB adenomas (6/8) were homogeneously enhanced.

In Japan, Sonazoid is used as the second-generation contrast agent for EUS for pancreaticobiliary or other abdominal diseases^{11,15,24-26,32-35}. Imazu *et al.* performed CH-EUS with Sonazoid and reported finding inhomogeneously enhanced patterns that indicated malignant GB wall thickening. In that report, the sensitivity, specificity and accuracy for conventional EUS vs CH-EUS for diagnosing malignant GB wall thickening were 83.3% vs 89.6%, 65.0% vs 98.0% ($p < 0.001$) and 73.1% vs 94.4% ($p < 0.001$), respectively. Specificity and accuracy for GB wall thickening were significantly higher for CH-EUS

than for conventional EUS. We retrospectively reviewed the efficacy of CH-EUS for diagnosing large (>10 mm) malignant and benign GB-protruding lesions¹⁷. In that review, the sensitivity, specificity, and malignant accuracy of CH-EUS were 100% (7/7), 94.1%, (16/17) and 95.8% (23/24), respectively. Cases treated at our hospital are presented in Figure 1.

CH-EUS for PC

CH-EUS using SonoVue or Sonazoid has been used to diagnose solid pancreatic lesions (SPLs)^{18,19,21,24,26,27,36}. CH-EUS can be utilized to clearly visualize SPL microvasculature and blood flow of the pancreatic parenchyma. PC has been observed as a hypoenhanced heterogeneous tumor on CH-EUS^{18,19,24,26,27} (Figure 2).

In 2008, Kitano *et al.* reported that on CH-EUS with SonoVue, hypovascular and heterogeneous images were observed for 80% (4/5) of malignant pancreatic lesions and isovascular images were ob-




Fig. 1. Enhanced pattern of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for gallbladder (GB) lesions.

- A. GB cancer was detected in a B-mode image.
- B. After contrast agent (Sonazoid) injection, GB cancer was enhanced heterogeneously in an extended pure harmonic detection (ExPHD)-mode image.
- C. GB adenoma was detected in a B-mode image.
- D. After contrast agent (Sonazoid) injection, GB adenoma was enhanced homogeneously in an ExPHD mode image.
- E. GB cyst was detected in a B-mode image.
- F. After contrast agent (Sonazoid) injection, a GB cyst was not enhanced in an ExPHD-mode image.




Fig. 2. Enhanced pattern of pancreatic cancer (PC) on contrast-enhanced harmonic EUS (CH-EUS) and CH-EUS-guided fine needle aspiration (CH-EUS-FNA).

- A. PC was imaged using B mode.
 B. (Left : B mode ; right : extended pure harmonic detection (ExPHD) mode) CH-EUS was performed and visualized using ExPHD mode. PC was hypoenhanced and enhanced heterogeneously on CH-EUS.
 C. (Left : B mode ; right : ExPHD mode) Fine needle aspiration was performed in the enhanced region of PC.

served for 100% (3/3) of pancreatitis lesions¹⁸). In 2010, Fusaroli *et al.* stated that hypoenhanced and inhomogeneous images on CH-EUS with Sono-Vue were a good identifier for diagnosing pancreatic adenocarcinoma. In 2014, Park *et al.* found that 57 out of 62 pancreatic adenocarcinomas produced hypoenhanced images on CH-EUS with Sono-Vue, which had a sensitivity of 92%, a specificity of 68% and an accuracy of 82%²⁷).

In 2012, Kitano *et al.* described findings obtained when using CH-EUS with Sonazoid to assess small (≤ 2 cm in diameter) SPLs²⁶). In this report, small pancreatic ductal carcinomas ($n=67$) appeared as hypoenhanced lesions, and the sensitivity and specificity of the tested imaging approach were 91.2% and 94.4%, respectively. This approach was superior to multidetector-row computed tomogra-

phy (which had a sensitivity of 70.6% and a specificity of 91.9%). Furthermore, these researchers reported sensitivities of 90.6% and 92.2% for CH-EUS and EUS-guided fine needle aspiration (EUS-FNA), respectively, in patients who underwent surgical resection of tumors ($n=91$), although sensitivity increased to 100% if findings for both procedures were considered.

CH-EUS-guided fine needle aspiration (CH-EUS-FNA) for SPLs

EUS-FNA is used to collect biopsy samples from many organs throughout the digestive tract and is useful for diagnosing SPLs³⁷⁻⁴⁰). The reported diagnostic accuracy, sensitivity, and specificity of EUS-FNA for SPLs are 85-89.4%, 82-94.7%, and 100%,

respectively⁴¹⁻⁴³). However, certain SPL patients could not be diagnosed via EUS-FNA. In 2015, Hou *et al.* described findings obtained using CH-EUS-FNA with Sono-Vue⁴⁴. They punctured SPLs after they had confirmed these lesions' enhanced patterns and retrospectively analyzed 58 cases involving CH-EUS-FNA and 105 cases involving EUS-FNA. Sufficient biopsy specimens were more frequently obtained in the CH-EUS group (96.6%) than in the EUS-FNA group (86.7%).

As mentioned above, PC appears as hypo-enhanced heterogeneous tumors on CH-EUS. Unenhanced areas reportedly reflect necrosis and fibrosis⁴⁵. Therefore, we performed CH-EUS-FNA by puncturing the enhanced region of SPLs³³ (Figure 2). In our report, sufficient biopsy samples were obtained with a single needle pass for 60% (12/20) of the CH-EUS-FNA group compared with 25% (5/20) of the conventional EUS-FNA group ($P=0.027$). In many cases, when EUS-FNA is performed, four needle passes are needed to obtain sufficient biopsy samples⁴⁶. In all reports about pancreatic tumor seeding associated with EUS-FNA, multiple needle punctures were performed⁴⁷⁻⁵¹. CH-EUS-FNA is expected to require a minimal number of needle passes.

Quantitative evaluation of CH-EUS for SPLs

In the reports described above, enhanced patterns were judged subjectively. However, as CH-EUS findings for SPLs have been subjected to objective quantitative analyses, a time-intensity curve (TIC) has been determined.

In 2011, Matsubara *et al.* observed that the rate of echo intensity reduction from the peak at one minute was greatest for PC, followed by mass-forming pancreatitis, autoimmune pancreatitis (AIP), and pancreatic neuroendocrine tumors²⁴. The reported sensitivity, specificity, and accuracy of EUS with a TIC were 95.8%, 92.6%, and 94.7%, respectively. In 2012, Imazu *et al.* reported that peak intensity and maximum intensity gain were significantly higher for AIP than for PC²⁵.

In 2015, Saftoiu *et al.* described TIC analysis with an artificial neural network classification model for diagnosing PC and chronic pancreatitis⁵². The sensitivity, specificity, positive predictive value, and negative predictive value for this approach were 94.64%, 94.44%, 97.24%, and 89.4%, respectively.

Conclusion

CH-EUS has been reported to be extremely effective in the diagnosis of pancreaticobiliary diseases. The combination of CH-EUS with EUS-FNA recently began being utilized; furthermore, techniques to quantitatively evaluate enhancement effects, such as determination of a TIC, have been performed. Procedures related to CH-EUS play a major role in the pancreaticobiliary field.

References

1. Sugiyama M, Atomi Y & Yamato T. Endoscopic ultrasonography for differential diagnosis of polypoid gall bladder lesions: analysis in surgical and follow up series. *Gut*, **46**: 250-254, 2000.
2. Kimura K, Fujita N, Noda Y, Kobayashi G & Ito K. Differential diagnosis of large-sized pedunculated polypoid lesions of the gallbladder by endoscopic ultrasonography: a prospective study. *J Gastroenterol*, **36**: 619-622, 2001.
3. DeWitt J, Devereaux B, Chriswell M, *et al.* Comparison of endoscopic ultrasonography and multi-detector computed tomography for detecting and staging pancreatic cancer. *Ann Intern Med*, **141**: 753-763, 2004.
4. Tamm EP, Loyer EM, Faria SC, Evans DB, Wolff RA & Charnsangavej C. Retrospective analysis of dual-phase MDCT and follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. *Abdom Imaging*, **32**: 660-667, 2007.
5. Azuma T, Yoshikawa T, Araida T & Takasaki K. Differential diagnosis of polypoid lesions of the gallbladder by endoscopic ultrasonography. *Am J Surg*, **181**: 65-70, 2001.
6. Abraham SC, Wilentz RE, Yeo CJ, *et al.* Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? *Am J Surg Pathol*, **27**: 110-120, 2003.
7. Weber SM, Cubukcu-Dimopulo O, Palesty JA, *et al.* Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma. *J Gastrointest Surg*, **7**: 129-137; discussion 137-129, 2003.
8. Hirooka Y, Naitoh Y, Goto H, Ito A, Taki T & Haya-kawa T. Usefulness of contrast-enhanced endoscopic ultrasonography with intravenous injection of sonicated serum albumin. *Gastrointest Endosc*, **46**: 166-169, 1997.
9. Mizuguchi M, Kudo S, Fukahori T, *et al.* Endoscopic ultrasonography for demonstrating loss of multiple-layer pattern of the thickened gallbladder wall in the preoperative diagnosis of gallbladder cancer. *Eur Radiol*, **7**: 1323-1327, 1997.

10. Hirooka Y, Naitoh Y, Goto H, *et al.* Contrast-enhanced endoscopic ultrasonography in gallbladder diseases. *Gastrointest Endosc*, **48** : 406-410, 1998.
11. Imazu H, Uchiyama Y, Matsunaga K, *et al.* Contrast-enhanced harmonic EUS with novel ultrasonographic contrast (Sonazoid) in the preoperative T-staging for pancreaticobiliary malignancies. *Scand J Gastroenterol*, **45** : 732-738, 2010.
12. Inui K, Yoshino J & Miyoshi H. Diagnosis of gallbladder tumors. *Intern Med*, **50** : 1133-1136, 2011.
13. Choi JH, Seo DW, Choi JH, *et al.* Utility of contrast-enhanced harmonic EUS in the diagnosis of malignant gallbladder polyps (with videos). *Gastrointest Endosc*, **78** : 484-493, 2013.
14. Park CH, Chung MJ, Oh TG, *et al.* Differential diagnosis between gallbladder adenomas and cholesterol polyps on contrast-enhanced harmonic endoscopic ultrasonography. *Surg Endosc*, **27** : 1414-1421, 2013.
15. Imazu H, Mori N, Kanazawa K, *et al.* Contrast-enhanced harmonic endoscopic ultrasonography in the differential diagnosis of gallbladder wall thickening. *Dig Dis Sci*, **59** : 1909-1916, 2014.
16. Xu JM, Guo LH, Xu HX, *et al.* Differential diagnosis of gallbladder wall thickening : the usefulness of contrast-enhanced ultrasound. *Ultrasound Med Biol*, **40** : 2794-2804, 2014.
17. Sugimoto M, Takagi T, Konno N, *et al.* The efficacy of contrast-enhanced harmonic endoscopic ultrasonography in diagnosing gallbladder cancer. *Sci Rep*, **6** : 25848, 2016.
18. Kitano M, Sakamoto H, Matsui U, *et al.* A novel perfusion imaging technique of the pancreas : contrast-enhanced harmonic EUS (with video). *Gastrointest Endosc*, **67** : 141-150, 2008.
19. Fusaroli P, Spada A, Mancino MG & Caletti G. Contrast harmonic echo-endoscopic ultrasound improves accuracy in diagnosis of solid pancreatic masses. *Clin Gastroenterol Hepatol*, **8** : 629-634 e621-622, 2010.
20. Ishikawa T, Itoh A, Kawashima H, *et al.* Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. *Gastrointest Endosc*, **71** : 951-959, 2010.
21. Napoleon B, Alvarez-Sanchez MV, Gincoul R, *et al.* Contrast-enhanced harmonic endoscopic ultrasound in solid lesions of the pancreas : results of a pilot study. *Endoscopy*, **42** : 564-570, 2010.
22. Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I & Pascu O. Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses. *Ultraschall Med*, **31** : 571-576, 2010.
23. Ang TL, Teo EK, Ang D, Kwek AB & Fock KM. A pilot study of contrast harmonic endosonography using DEFINITY in the evaluation of suspected pancreatic and peri-ampullary malignancies. *J Interv Gastroenterol*, **1** : 160-165, 2011.
24. Matsubara H, Itoh A, Kawashima H, *et al.* Dynamic quantitative evaluation of contrast-enhanced endoscopic ultrasonography in the diagnosis of pancreatic diseases. *Pancreas*, **40** : 1073-1079, 2011.
25. Imazu H, Kanazawa K, Mori N, *et al.* Novel quantitative perfusion analysis with contrast-enhanced harmonic EUS for differentiation of autoimmune pancreatitis from pancreatic carcinoma. *Scand J Gastroenterol*, **47** : 853-860, 2012.
26. Kitano M, Kudo M, Yamao K, *et al.* Characterization of small solid tumors in the pancreas : the value of contrast-enhanced harmonic endoscopic ultrasonography. *Am J Gastroenterol*, **107** : 303-310, 2012.
27. Park JS, Kim HK, Bang BW, Kim SG, Jeong S & Lee DH. Effectiveness of contrast-enhanced harmonic endoscopic ultrasound for the evaluation of solid pancreatic masses. *World J Gastroenterol*, **20** : 518-524, 2014.
28. Sanchez MV, Varadarajulu S & Napoleon B. EUS contrast agents : what is available, how do they work, and are they effective ? *Gastrointest Endosc*, **69** : S71-77, 2009.
29. Piscaglia F, Nolsoe C, Dietrich CF, *et al.* The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS) : update 2011 on non-hepatic applications. *Ultraschall Med*, **33** : 33-59, 2012.
30. Sugiyama M, Xie XY, Atomi Y & Saito M. Differential diagnosis of small polypoid lesions of the gallbladder : the value of endoscopic ultrasonography. *Ann Surg*, **229** : 498-504, 1999.
31. Sadamoto Y, Oda S, Tanaka M, *et al.* A useful approach to the differential diagnosis of small polypoid lesions of the gallbladder, utilizing an endoscopic ultrasound scoring system. *Endoscopy*, **34** : 959-965, 2002.
32. Kitano M, Kamata K, Imai H, *et al.* Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliary diseases. *Dig Endosc*, **27 Suppl 1** : 60-67, 2015.
33. Sugimoto M, Takagi T, Hikichi T, *et al.* Conventional versus contrast-enhanced harmonic endoscopic ultrasonography-guided fine-needle aspiration for diagnosis of solid pancreatic lesions : A prospective randomized trial. *Pancreatol*, **15** : 538-541, 2015.
34. Xia Y, Kitano M, Kudo M, *et al.* Characterization of intra-abdominal lesions of undetermined origin

- by contrast-enhanced harmonic EUS (with videos). *Gastrointest Endosc*, **72** : 637-642, 2010.
35. Sakamoto H, Kitano M, Matsui S, *et al.* Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS (with videos). *Gastrointest Endosc*, **73** : 227-237, 2011.
 36. Michiko Y, Yoshimitsu Y, Yasuyuki S & Hideyuki H. Education and Imaging. *Gastrointestinal : contrast-enhanced harmonic EUS for pancreatic cancer*. *J Gastroenterol Hepatol*, **24** : 1698, 2009.
 37. Vilmann P, Jacobsen GK, Henriksen FW & Hancke S. Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease. *Gastrointest Endosc*, **38** : 172-173, 1992.
 38. Bhutani MS, Hawes RH, Baron PL, *et al.* Endoscopic ultrasound guided fine needle aspiration of malignant pancreatic lesions. *Endoscopy*, **29** : 854-858, 1997.
 39. Voss M, Hammel P, Molas G, *et al.* Value of endoscopic ultrasound guided fine needle aspiration biopsy in the diagnosis of solid pancreatic masses. *Gut*, **46** : 244-249, 2000.
 40. Chang KJ, Katz KD, Durbin TE, *et al.* Endoscopic ultrasound-guided fine-needle aspiration. *Gastrointest Endosc*, **40** : 694-699, 1994.
 41. Williams DB, Sahai AV, Aabakken L, *et al.* Endoscopic ultrasound guided fine needle aspiration biopsy : a large single centre experience. *Gut*, **44** : 720-726, 1999.
 42. Eloubeidi MA, Jhala D, Chhieng DC, *et al.* Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. *Cancer*, **99** : 285-292, 2003.
 43. Ryozaawa S, Kitoh H, Gondo T, *et al.* Usefulness of endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of pancreatic cancer. *J Gastroenterol*, **40** : 907-911, 2005.
 44. Hou X, Jin Z, Xu C, *et al.* Contrast-enhanced harmonic endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of solid pancreatic lesions : a retrospective study. *PLoS One*, **10** : e0121236, 2015.
 45. D'Onofrio M, Zamboni G, Tognolini A, *et al.* Mass-forming pancreatitis : value of contrast-enhanced ultrasonography. *World J Gastroenterol*, **12** : 4181-4184, 2006.
 46. Suzuki R, Irisawa A, Bhutani MS, *et al.* Prospective evaluation of the optimal number of 25-gauge needle passes for endoscopic ultrasound-guided fine-needle aspiration biopsy of solid pancreatic lesions in the absence of an onsite cytopathologist. *Dig Endosc*, **24** : 452-456, 2012.
 47. Micames C, Jowell PS, White R, *et al.* Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. *Gastrointest Endosc*, **58** : 690-695, 2003.
 48. Paquin SC, Garipey G, Lepanto L, Bourdages R, Raymond G & Sahai AV. A first report of tumor seeding because of EUS-guided FNA of a pancreatic adenocarcinoma. *Gastrointest Endosc*, **61** : 610-611, 2005.
 49. Ahmed K, Sussman JJ, Wang J & Schmulewitz N. A case of EUS-guided FNA-related pancreatic cancer metastasis to the stomach. *Gastrointest Endosc*, **74** : 231-233, 2011.
 50. Chong A, Venugopal K, Segarajasingam D & Lisewski D. Tumor seeding after EUS-guided FNA of pancreatic tail neoplasia. *Gastrointest Endosc*, **74** : 933-935, 2011.
 51. Katanuma A, Maguchi H, Hashigo S, *et al.* Tumor seeding after endoscopic ultrasound-guided fine-needle aspiration of cancer in the body of the pancreas. *Endoscopy*, **44 Suppl 2 UCTN** : E160-161, 2012.
 52. Saftoiu A, Vilmann P, Dietrich CF, *et al.* Quantitative contrast-enhanced harmonic EUS in differential diagnosis of focal pancreatic masses (with videos). *Gastrointest Endosc*, **82** : 59-69, 2015.